Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cell Therapeutics Inc. (CTIC US) rose 8.9 percent to $1.10 after gaining 16 percent earlier, the biggest intraday rise since Dec. 6. The Food and Drug Administration said the company’s pixantrone, which is under review for adults with non- Hodgkin’s lymphoma who received two or more prior lines of therapy, will be discussed by an advisory committee on Feb. 9.
Steven Derby and SDS Capital Reveal Stake in Guided Therapeutics - cbl
Posted April 24, 2011 By Richard Rabicoff
http://newyork.citybizlist.com/18/2011/4/24/Steven-Derby-and-SDS-Capital-Reveal-Stake-in-Guided-Therapeutics--cbl.aspx
NEW YORK -- Steven Derby and his SDS Capital Management, LLC reported that they own 180,403 shares or 0.39 percent of Guided Therapeutics, Inc. (OTCBB and OTCQB: GTHP).
The holdings are worth $162,362 at the Guided Therapeutics Friday closing price of $0.90 per share.
Norcross, Ga.-based Guided Therapeutics is a medical device company focused primarily on the Light Touch cervical cancer detection technology and extension of its biophotonics detection platform into other cancers, especially lung and esophageal.
For 2010, the company's revenue was approximately $3.3 million versus approximately $1.6 million for 2009. For the year, the net loss was $4.5 million, or $0.12 per share, compared to a net loss of $6.4 million, or $0.38 per share, in 2009.
Guided Therapeutics recently announced the extension of its contract with Konica Minolta Opto to develop a product that will help detect and monitor a pre-cancerous condition of the esophagus.
The company is led by Dr. Mark L. Faupel Ph.D., who serves as chief executive officer, president, chief operating officer, acting chief financial officer, and principal accounting officer.
Derby, who holds an MBA from the Stanford School of Business, started SDS Capital in 2000. The Old Greenwich, Conn.-based firm is a life sciences investment boutique that has invested in such companies as Forticell BioScience, Inc., Telenetics, Corp., Entremed, and Echo Therapeutics, Inc.
OriginOil Receives "50 Hottest Companies in Bioenergy" Award
55 minutes agoBusiness Wire
"Proven elite of the bioenergy world" honored at Advanced Biofuels Leadership Conference
LOS ANGELES & WASHINGTON--(BUSINESS WIRE)--Apr. 21, 2011-- OriginOil, Inc. (OOIL), the developer of breakthrough technology to transform algae, the most promising source of renewable oil, into a true competitor to petroleum, today announced it was among fifty companies honored as 2010's bioenergy leaders at the Advanced Biofuels Leadership Conference in Washington, DC, which concludes today.
CEO Riggs Eckelberry accepts the "50 Hottest Companies in Bioenergy" Award from Biofuels Digest editor Jim Lane at the Advanced Biofuels Leadership Conference, April 19, 2011. (Photo: Business Wire)
Jim Lane, editor of conference organizer Biofuels Digest, led the award ceremony on the first evening of the conference. He said, "I don’t think people realize how hard it is to make the cut as a '50 Hottest Company'.
"This year, the field of qualified companies widened to 1400. We had over 80,000 votes from subscribers, and our panel of 100 International Selectors finalized the rankings.
"Whether Number One or Number Fifty, this is the proven elite of the bioenergy world."
In this year’s competition, OriginOil advanced to Number 33 overall, one of just five algae companies that made the top fifty.
Editor Jim Lane said: "OriginOil was one of the biggest gainers this year – only 25 or so companies have now appeared in all three Hot 50 polls."
"The Advanced Biofuels Leadership Conference this year was a sellout success, and we commend Jim Lane’s team for making this one of the finest conferences of the year," said Riggs Eckelberry, OriginOil CEO. "We look forward to competing again this year."
Edmunds: Japan quake could hurt 2011 US auto sales
10 minutes ago Reuters
* Edmunds: April US sales seen 13.3 million on annual rate
* Early April sales show $120-per-vehicle price rise in US
By Bernie Woodall
DETROIT, April 15 (Reuters) - Severe supply disruptions in the wake of Japan's earthquake could slow the gradual recovery of the U.S. auto industry just as it was starting to gain momentum.
Analyst Edmunds.com said the earthquake and its aftermath could cut 2011 U.S. auto sales to a rise of 6 percent over 2010 instead of the 12 percent rise that is currently forecast.
Edmunds said on Friday that the lack of parts to build vehicles will cut into available U.S. auto inventory and sales this summer, when small-car demand is expected to peak due to high gasoline prices, but automakers are likely to make up those lost sales later in the year.
Edmunds is maintaining its 12 percent growth forecast for this year.
Small-car leaders based in Japan, Toyota Motor Corp <7203.T>, and Honda Motor Co <7267.T> face crimped supply due to production cuts.
"At this point we're still optimistic that any supply constraints will only slide summer sales to later in the year when automaker production is expected to be back to normal," said Lacey Plache, Edmunds chief economist.
Plache said that Edmunds' 2011 forecast of 12.9 million new auto sales could fall to 12.6 million if supply disruptions and lower production are "moderate," and 12.2 million if they are "severe."
Last year, U.S. auto sales were 11.5 million units, an 11 percent gain over 2009 sales, which were the lowest in almost three decades.
These figures do not include medium and heavy trucks.
Edmunds said U.S. April sales of new light vehicles are likely be near 13.3 million on a seasonally adjusted annualized basis, up 19 percent from April 2010.
Prices monitored by Edmunds are up $120 per vehicle, based on early April sales.
Edmunds analyst Ray Zhou said that early April sales would indicate a pace of 14.1 million on a seasonally adjusted annual rate, but that it is likely the first month of spring will show sales of 13.3 million on the adjusted annual basis.
Lean inventories of some models, primarily small fuel-efficient cars as gasoline prices rise toward $4 per gallon, and concerns about product availability in the aftermath of the earthquake have prompted many U.S. consumers to rush their purchases ahead of a perceived shortage for some models, said Jeremy Anwyl, Edmunds chief executive.
Small-car prices are on the rise the most, due to the thinning of inventory due to the Japan crisis, said Zhou. Cars are also spending less time on dealer lots than they were a short time ago, Zhou said.
Fewer small cars and fewer days on a dealer lot, Zhou said, are "laying a foundation for future price increases due to the potential shortage."
In March, U.S. light vehicle sales were 13.1 million on a seasonally adjusted annualized rate. Using the same basis, April 2010 sales were 11.2 million, and April 2009 sales were 9.2 million, during one of the lowest monthly sales rates of the 2008-2009 downturn for the auto industry. (Reporting by Bernie Woodall, editing by Matthew Lewis)
IceWEB Partner Thermopylae Science and Technology (TST) Awarded Contract From a Department of Defense Agency for Two Large Enterprise Unified Storage Platforms
6 minutes ago PR Newswire
STERLING, Va., April 15, 2011 /PRNewswire/ -- IceWEB, Inc. (OTCBB: IWEB), www.IceWEB.com, a leading provider of Unified Data Storage and building blocks for cloud storage networks, announced today that TST will deploy two IceWEB 3000 Series Unified Data Storage Systems to power its Google™ Earth Enterprise Visualization and Mobile computing platforms for the DOD. Iceweb Storage Platforms provide the performance and storage capacity required by TST's iSpatial Geospatial 3-D Visualization and Tracking System.
"TST's iSpatial software framework coupled with IceWEB's storage and Google's Earth Enterprise product enables customers to visualize limitless amounts of data on a 3-D globe," said John R. Signorello, IceWEB CEO. "iSpatial integrates with virtually any data source and can manage real-time information and mobile messaging directly from a web-based user interface. We're proud to be part of the TST team that is both transforming and expanding the Geospatial market in the government and private market sectors."
Each IceWEB Model 3000 HC System will ship with 104 Terabytes and two 10 GB Ethernet interfaces for iSCSI and NAS connectivity. All IceWEB Unified Storage Systems support both file and block data, structured or unstructured, in both the cloud and data center environments. A complete array of storage management features are available including in-line de-duplication, compression and thin provisioning for unparalleled storage efficiency rates.
IceWEB and Promark Technology are working in tandem to ship this prototype order to a classified Department of Defense Agency. IceWEB and Promark are collaborating on this order to provide an expeditious turnaround on the delivery of this enterprise storage solution.
I've got a full-brain wireless electroencephalogram sensor headset on - I'm staring at my charts - and pushing the share price and volume of JEDM upward - with my mind!
Too bad the markets closed!
Seriously, I have little doubt that this technology will catch on and take off. But there's still a big risk involved at this point. They are in the final phases of a developmental stage company, and need to begin production and distribution. A lot depends on the next steps that management takes. Just have to wait to see.
IceWEB and Promark Reach Merger Agreement; Cloud, Virtual Storage a Focus
IceWEB Inc., a provider of unified data storage and building blocks for cloud storage networks and Promark Technology Inc., a distributor of data storage products and solutions have announced a definitive merger agreement.
by Vance McCarthy
http://www.idevnews.com/stories/4617/IceWEB-and-Promark-Reach-Merger-Agreement-Cloud-Virtual-Storage-a-Focus
IceWEB Inc., a provider of unified data storage and building blocks for cloud storage networks and Promark Technology Inc., a distributor of data storage products and solutions have announced a definitive merger agreement.
“The combined company will be a data storage powerhouse with over 1200-plus channel partners and a leading 128 bit file system platform,” John Signorello, Chairman and CEO of IceWEB said in a statement. As one entity, we will have all the missing piece(s) of the puzzle necessary for sustained growth and success in the data storage space.”
“We are very excited and see great potential in this merger,” said Dale Foster, Promark’s President, in a statement. “Our experience marketing the IceWEB Storage Appliance line of products quickly brought us to the realization that IceWEB’s unified storage approach gave it a competitive edge, and one that could very rapidly carve out a significant share of the market.”
Among its offerings, IceWEB provides options to support virtual server environments with shared storage to simplify management, ensure data availability, enables efficient backup, and provides virtual data storage support, relocation and migration. IceWeb products include:
IceWEB Storage System -- Centralizes key storage and VM management tasks.
IceWEB's VM Manager -- Unified management console for controlling all storage-related aspects of a virtualized infrastructure for VMware ESX, Citrix Xen, and Microsoft Hyper-V environments.
In early April, IceWEB’s NAS (Network Attached Storage) systems were officially certified by VMware as VMware Ready. To receive this accreditation, IceWEB Unified Storage NAS Systems passed all VMware lab tests and met all the integration and interoperability criteria.
Promark Technology, a 26-year-old privately held firm, has extensive network of some 1,200 value added resellers in the U.S. and operates at a $100 million annual revenue run rate, with no debt, officials said.
Promark has acted as the channel distributor for some of the leading storage companies including EqualLogic (acquired by Dell), LeftHand Networks (acquired by HP), Data Domain (acquired by EMC) and Compellent (acquired by Dell).
Last June, Promark acquired Niksar Data Management LLC, a professional services organization that plans, designs, and installs enterprise storage systems. That firm became Promark Professional Services, which offers services exclusively through Promark’s Value Added Reseller Channel.
World Water Works has some major league clients. . . . Siemens, Birds Eye Foods, Butterball, Hormel Foods, Cintas, Con Agra, Del Monte, Intel, Este Lauder, Abott Labs. . . At the very least, this will bring about major awareness, interest and recognition of Original Oil and it's technology. Home run Riggs!
OOIL - What a GEM!
Was begining to think that I may have invested too much, but now I don't think it's enough. Gonna start buying in again. This thing should snowball, and will as soon as they start getting some hard numbers from sales! Looking forward - looking good!
Just opened my e-mail - - Came here to post the newsletter. Ha, it's already here
Would like to get more details on this.
Has agreed in principle to distribute. . . .
http://www.algaeindustrymagazine.com/world-water-works-ahto-system-for-algae-%20harvesting/
http://www.worldwaterworks.com/
I've been waiting for this one
Ford Bets On Its Own Future With Unusual Bond Deal
39 minutes agoDow Jones
By Kellie Geressy-Nilsen and Anusha Shrivastava
Of DOW JONES NEWSWIRES
NEW YORK (Dow Jones)--Ford Motor Credit Co. (F) was offering a $1.5 billion five-year asset-backed bond Tuesday that will convert to senior unsecured debt if two of three credit firms raise the auto maker's rating to investment grade, an unusual structure that investors interpreted as a sign of Ford's confidence in its near-term future.
"Ford is a good credit story and this structure gives them some flexibility," said Paul Norris, head of structured products at Dwight Asset Management Co. in Burlington, Vt., which is looking to bid for the deal. "This is a new kind of funding for them and because they have done a good job of managing their balance sheet, demand for a $1 billion deal is $6 billion."
The deal was increased in size from $1 billion, a sign of robust investor appetite.
Ford was the only U.S. auto maker to avoid bankruptcy and overtook General Motors last month as the country's best-selling car maker. Ford was the top issuer of asset-backed bonds last year.
The latest issue, the Ford Upgrade Exchange Linked Notes, is being sold via the FUEL Trust 2011-1, according to an offering document.
As suggested by the name, the issue features an upgrade and exchange. As issued, the so-called FUEL notes will be investment-grade asset-backed securities. However, if any two of the three major ratings firms--Moody's Investors Service, Standard & Poor's and Fitch Ratings--raise Ford Motor Credit's senior unsecured credit rating to investment grade, the FUEL notes must be exchanged into Ford Motor Credit senior unsecured notes, keeping the identical maturity and coupon of the original FUEL issue.
S&P rates Ford's unsecured debt BB-minus, three notches below investment grade. Fitch rates the auto maker's unsecured debt one notch higher, at BB. Moody's rates the unsecured debt Ba2.
"It's basically investment-grade debt given it's backed by prime auto receivables," Norris said. "They are trying to be creative and get to new participants. This is a cross-over type of deal so both investors in corporates and securitized products could be interested in buying the deal, hence so much interest in it."
The $1.5 billion noncallable issue is to be sold in the private placement Rule 144a market, which is aimed at institutional investors, via joint bookrunners Citigroup, Bank of America Merrill Lynch and Goldman Sachs.
The deal has launched at a risk premium of 200 basis points over Treasurys. Price guidance was 210 basis points over Treasurys.
"We think they are priced attractively," Norris said. "People are going to jump all over it."
The underlying collateral for the notes is Ford Credit Auto Owner Trust 2011-SRR1's note issue. That deal is a securitization of a revolving pool of car, light truck and utility vehicle receivables purchased by Ford Credit from dealers and is rated BBB- by S&P.
The FUEL deal has been rated Baa2 by Moody's Investors Service and BBB- by Standard & Poor's.
Margaret Mellott, a Ford spokeswoman, declined to comment.
-By Anusha Shrivastava, Dow Jones Newswires; 212-416-2227; anusha.shrivastava@dowjones.com
04-12-11 1442ET
Copyright (c) 2011 Dow Jones & Company, Inc.
OriginOil Among Eight “Technologies to Rock the Bio World”
Posted: 12 Apr 2011 10:44 AM PDT
Today in Biofuels Digest, Jim Lane writes about “Transformers: Eight Technologies to Rock the Bio World.” Two are closely algae-related and one covers the extraction work we’re doing at OriginOil.
Here they are:
5. Algae extraction.
While we are on the subject of the special challenges of growing algae, there’s the problem of getting the algae out of the water, or the water out of the algae. Given that a decent microalgae concentration is around 0.1 percent, you have to remove 1000 gallons of water per gallon to get a gallon of dry algal biomass, which has about 50,000 BTUs or so. So even if you are expending just a handful of BTUs per gallon to move the water, you’re dangerously close to using more energy to produce algal fuels than the fuel contains.
That’s why consortia such as the NAABB have made this is high priority, and it ranks near the top of the problem chart in the Algal Technology Roadmap developed by the DOE. Companies such as Solazyme and Aurora Algae say they have proprietary solutions, and companies like OriginOil and AlgaeVenture Technologies have been developing solutions for license. For sure, no algae fuel company will emerge at scale without a solution to this one.
And the other:
6. 30 ton per acre (per year) sustainable biomass production.
At 40 tons per acre per year – generally at this time only achievable with a handful of terrestrial plant forms, and algae – opens up the potential capacity of systems. Remember, key to making renewable fuels economical is scale, and key to scale is how far you can affordably transport biomass, and how much production land can be sustainably put to work to deliver biomass to a given plant. A 20-square mile plantation, at those production rates (assuming you can locate all the nutrients), yields 192,000 tons of biomass, enough, for example, to supply 50 million gallons of cellulosic ethanol.
Algal growth technologies are, generally, well on the way to making this an every day reality. 25 gram per square meter per day systems equate to about 36 tons of biomass per acre per year, and that’s becoming table stakes in algal development. But not everyone can use, or grow, algae, and that form of biomass has its own set of special challenges. A 30 ton per acre, sustainably produced, wood or terrestrial crop? Game changer.
Hydrogen, another area we are working in, is also mentioned as a Transformer, and we certainly agree.
I have no doubt.
Maryland House Passes Watered Down Medical Marijuana Affirmative Defense Bill
http://safeaccessnow.org/article.php?id=6357
Thanks, was interesting.
Novartis AG Seals Alcon, Inc. Deal With $463 Million Cash Payment-Reuters
Friday, 8 Apr 2011 05:55am EDT
Reuters reported that Novartis AG has finally sealed its $50.9 billion buy of Alcon Inc by paying the eyecare group's minority shareholders an extra $463 million in cash. Alcon minority shareholders are getting 2.9228 Novartis shares, up from the originally announced 2.8 as this includes a dividend adjustment, as well as $8.20 in cash per share, meaning that each shareholder gets $168 per Alcon share. Novartis spent pretty much all of last year trying to clinch 100% ownership of Alcon, but its original all paper offer of 2.8 shares for each Alcon share met stiff resistance from Alcon's Independent Director Committee, which repeatedly dismissed this bid as grossly inadequate. Novartis eventually sweetened its bid with a cash component last December to ensure the Alcon shareholders receive $168, the average price Novartis paid for Nestle's 77% stake in Alcon. Both Novartis and Alcon shareholders have now backed the merger, which Novartis is hoping will help it to diversify and give it protection against patent losses on big selling medicines such as blood pressure drug Diovan.
Ohhh Nehhllee Shishkova, you're a little monkey woman. You know that? You're a little monkey woman.
http://www.hotstocked.com/article/4453/imaging3-inc-otc-imgg-continues-the-fall.html
Consent of Independent Registered Public Accounting Firm
We consent to the use in this Amendment No. 2 to Registration Statement (No. 333-172258) on Form S-1 of Advanced Cell Technology, Inc. and subsidiary of our report dated March 16, 2011, relating to our audit of the consolidated financial statements, appearing in the Prospectus, which is a part of this Registration Statement.
We also consent to the reference to our firm under the caption “Experts” in such Prospectus.
SingerLewak LLP
Los Angeles, California
April 7, 2011
S1 (Amended)
The initial registration form for new securities required by the Securities and Exchange Commission (SEC) for public companies. Any security that meets the criteria must have an S-1 filing before shares can be listed on a national exchange.
Form S-1 requires companies to provide information on the planned use of capital proceeds, detail the current business model and competition, as well provide a a brief prospectus of the planned security itself, offering price methodology, and any dilution that will occur to other listed securities. The SEC also requires the disclosure of any material business dealings between the company and its directors and outside counsel.
Form S-1 is also known as the "Registration Statement Under the Securities Exchange Act of 1933".
Investopedia Says
Investopedia explains SEC Form S-1
Investors can view S-1 filings online to perform due diligence on new offerings prior to their issue. The form is sometimes amended as material information changes or general market conditions cause a delay in the offering.
The Securities Exchange Act of 1933, often referred to as the "truth in securities" law, requires that these registration forms are filed to disclose important information upon registration of a company's securities. This helps the SEC achieve the objectives of this act, which is requiring investors to receive significant information regarding securities offered, and to prohibit fraud in the sale of the offered securities.
A less rigid registration form is the S-3, which is for companies that don't have the same ongoing reporting requirements.
Novartis Curbs US Submission For Afinitor Use In Cancer Tumors
19 minutes agoDow Jones
By Katharina Bart
Of DOW JONES NEWSWIRES
ZURICH (Dow Jones)--Novartis AG (NVS) Friday said it will limit its application for cancer drug Afinitor in the U.S. to one type of cancerous tumor only, dealing a potential blow to the Swiss drugmaker's pipeline of new treatments.
The Basel-based firm said it is now asking the U.S. Food and Drug Administration to approve Afinitor only to treat advanced pancreatic neuroendocrine tumors, a rare form of cancer that has recently received broader attention after it became public that Apple Inc. (AAPL) Chief Executive Steve Jobs had the disease.
This means that Novartis is effectively dropping Afinitor to treat advanced neuroendocrine tumors of gastrointestinal and lung origin after feedback from the health regulator.
"Novartis remains committed to patients with advanced neuroendocrine tumors and will continue to conduct studies in patients with advanced carcinoid tumors, where there is a critical unmet need," the company said.
Afinitor is also being studied in late-stage clinical trials for several other cancers, including advanced breast cancer. The drug, which in 2010 more than tripled sales to $243 million, is expected by analysts to become a blockbuster with more than $1 billion in annual sales.
Had Afinitor been able to clinch approval to treat different cancer types it could have--together with multiple-sclerosis pill Gilenya, which could net more than $3 billion in annual peak sales--helped reduce the sales loss impact from the patent expiry of heart drug Diovan.
Diovan, Novartis' best-selling drug, which had annual sales of more than $6 billion in 2010, will start to lose patent protection in some markets this year. Likewise, cancer medicine Femara, which has more than $1 billion in revenue, will face generic competition in 2011, which is likely to result in a steep sales slump. Depending on the number of generic entrants, sales can drop more than 50% after patent rights mature.
Novartis has said that, while it will continue to stick to its strategy of a diversified pharmaceutical company--the firm also owns a large generics, vaccines and eye-care treatment business--the Swiss drugs giant will push for the development of new drugs.
With more than 10% of its sales going into research and development, Novartis wants to boost the ratio of its specialized medicines over the next few years. Currently, Novartis generates around 20% of its drug sales with medicines that have recently been launched.
-By Katharina Bart, Dow Jones Newswires; +41 43 443 8043; katharina.bart@dowjones.com
A Radio Visit to OriginOil
Good morning!
It was 1992, and Los Angeles http://www.kcrw.com/news/programs/ww was in flames. And "Which Way, L.A.?" became the daily must-listen show to cover the events. It's since expanded to cover US and global affairs.
This week, it covered OriginOil! You can listen to it http://www.kcrw.com/media-player/mediaPlayer2.html?type=audio&id=ww110407will_renewable_energ . (Click "Listen" and move the slider to the 11 minute mark, where our segment begins.)
We tour the lab and explain how algae is being developed into fuels and other products, and the part we play. We think it's very, very good.
If you have a moment today, please do listen to the program! Let me know what you think.
Algae's "Killer App"
Great new video on our home page http://www.originoil.com/. Check it out. The short clip features my speech last week at the NAA in New York, our Australian pilot site, and some kind words from Barry Cohen, Executive Director of the NAA.
Key points in the video: algae's "killer app" (taking advantage of its ability to absorb CO2), and our new effort to integrate our technology with other vendors.
Integration is logical, and customers are clamoring for it.
Linking up with Other Vendors
Here's how it works out in practice. Say there is a device that works before or after our own technology in the algae production process. It's a standard piece of equipment that is distributed throughout the world.
So we make sure our two technologies work together; and then we agree to bring their product into our sites, and they will do the same for their international network.
A series of agreements like this will ensure that we acquire global distribution for our technology, while solving major challenges for our customers.
I wouldn't be talking about this if we didn't have something in the works, so stay tuned!
And here's to a great weekend.
Riggs and team
Riggs Eckelberry
President & CEO
OriginOil, Inc. (OOIL)
Impax Laboratories Enters into Commercialization Agreement with Banner Pharmacaps
HAYWARD, Calif. & HIGH POINT, N.C., Apr 08, 2011 (BUSINESS WIRE) --
Impax Laboratories, Inc.(NASDAQ: IPXL) today announced that it will collaborate with Banner Pharmacaps Inc. with respect to the supply and commercialization of two softgel capsule products. The products and terms of the agreement were not disclosed.
Larry Hsu, Ph.D., president and CEO of Impax Laboratories, said: "We are excited to collaborate with Banner, a global leader in developing and manufacturing softgel products. In less than a year, we have entered into four distinct partnerships for alternate dosage form products as we continue to execute our strategy of diversifying our product base. Our business development activities will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms."
Roger E. Gordon, Ph.D., president and CEO of Banner Pharmacaps Inc., added: "We are delighted to be joining forces with Impax, a specialty pharmaceutical company whose vision and goals so closely mirror those of Banner. They join our expanding list of partners who look to Banner to provide expertise in the development of gelatin-based drug delivery systems and unique technology platforms."
Huntsman Jumps After Saying First-Quarter Pigment Profit Rose
By Jack Kaskey - Apr 7, 2011 10:41 AM PT
Huntsman Corp. (HUN), the world’s third- biggest producer of titanium-dioxide pigment, gained in New York trading after the company said profit margins for the white paint ingredient widened in the first quarter.
Huntsman increased prices about $400 a ton in the quarter and each $100 gain adds $50 million to earnings before interest, tax, depreciation and amortization, Chief Executive Officer J. Kimo Esplin said today in a presentation on the company’s website. Rising raw-material costs will erode some of the margin expansion, he said.
“We’re going to still expand margins and we’re going to expand them at a pretty good rate,” Esplin said. “Just don’t forget the headwinds that we are all experiencing.”
Huntsman, which is run from offices in Salt Lake City and The Woodlands, Texas, rose as much as 7 percent and was 99 cents, or 5.6 percent, higher at $19.10 as of 1:18 p.m. in New York Stock Exchange composite trading.
The largest titanium dioxide maker is DuPont Co., followed by Cristal Global, Esplin said. The chemical adds opacity and whiteness in paints, plastics and paper.
XOMA, Ltd. (XOMA) got pounded over the last few weeks after a failed diabetes drug trial, but is earning huge message board buzz today about a possible short squeeze. Too early to tell, but this drug developer’s stock popped close to 13% from the opening bell and volume is shaping up strong.
http://www.quote.com/us/stocks/quote.action?s=XOMA
It's a mess. Seemed to be a good company with outstanding products, but as we see too often now a days they suffered from too much debt and careless management.
The best I can tell is that they have finally reached an agreement with creditors and have issued new FRN's in exchange for outstanding debt, Wells Fargo has taken over assets creating something called a DIP Facility (Debtor In Possession). If I read and understand correctly a complete restructuring of the company, new issue of stock, and new board members. Can't find anything definite about current equity-holders. But it don't look to good.
There are tons of articles and opinions if you google angiotech bankruptcy. Their website has links to A&M's website were they have a document history of petitions filed. Fortunately for me, I only have a small stake in the company, so I will hold on to see what comes of all this. It'll be a learning experience.
been thinking the same
Gotcha, thnx.
I'm no expert, but this looks like it's a company contribution. An indirect ownership 401K, probably part of his retirement package - 5,000 share acquired. What's odd is that OMB Number (Office of Management and Budget) expired in January 2005?
(2) Held indirectly under the XOMA Ltd. Deferred Savings Plan.
Thanks for the effort and sharing that. Just might put some suspicions to rest. But carndog, I wouldn't call yourself a whole!
Okay, maybe not so flat after all . . . June 1st!
http://www.azdhs.gov/prop203/
Absolutely. I don't like to make predictions, especially about the future, but. . . 20+ late summer—early fall, barring anymore unforeseen world disasters.
Affected Creditors Unanimously Approve Second Amended and Restated CCAA Plan of Compromise or Arrangement
VANCOUVER, April 4 /CNW/ - Angiotech Pharmaceuticals, Inc. ("Angiotech" or the "Company") today announced that the affected creditors of Angiotech and certain of its subsidiaries (collectively, the "Angiotech Entities") have unanimously approved the Second Amended and Restated Plan of Compromise or Arrangement (as amended from time to time, the "Amended Plan") concerning, affecting and involving the Angiotech Entities pursuant to the Companies' Creditors Arrangement Act (Canada).
The Angiotech Entities are scheduled to seek an order of the Supreme Court of British Columbia (the "Court") sanctioning the Amended Plan on April 6, 2011. Should the Court approve the Amended Plan, the Angiotech Entities will proceed with the implementation of the Amended Plan following the satisfaction or waiver of all conditions precedent.
At the meeting of affected creditors today, Alvarez & Marsal Canada Inc. (the "Monitor"), in its capacity as the Court-appointed monitor, reported that 100% of the votes registered by the Angiotech Entities' affected creditors were in favour of the Amended Plan.
To be accepted, the Amended Plan required approval by a majority in number representing at least two-thirds of the total value of the affected creditors' voting claims.
More information about the Angiotech Entities' restructuring process can be found at http://www.angiotech.com and on the website of the Monitor, at http://www.alvarezandmarsal.com/angiotech.
Look for a big run up tomorrow. . . .
Stock Preacher and company are starting to pump. . . .
Cell Therapeutics, Inc. (CTIC) is in play this morning after a medical journal reported that a recent FDA trial of the company's cancer treatment worked on up to 80% of the test subjects. The news not only gave the stock a lift but pushed it up through the 10 Day Moving Average.
http://www.quote.com/us/stocks/quote.action?s=CTIC
StockPreacher
Neo—
I'm in this one for the long haul, and remain very optimistic about the future of this industry and in particular this company. It's almost a year now since I started buying shares of GRNH.
However, if what happened after California's Prop defeat on November 2nd is any indication of how the market will respond to today's defeat, then I can only see this company and other med marijs taking a hit for the next few days and then remaining flat for some time. MJNA -27.59%, PCIO down 20% CBIS down 1.32% today. The results may not be as dramatic as they were last fall, a state the size of California carries a lot of weight. In my opinion the recent increase in volume and price can only be attributed to an increase in speculation over the outcome of today's decision. And there will be those who were disappointed and are looking to bail-out.
For now July & 241 thousand signatures are a long way off. November even longer. In the meantime I'll just keep accumulating and supporting. The time for GRNH will come - just not right now.
. . . All in all, I'd rather you be right, please prove me wrong. I'm a contrary by nature!
There should be a sell-off tomorrow, back down to .015.
Impax Laboratories Confirms Patent Challenge Relating to DEXILANT(R) Delayed-ReleaseCapsules, 30 mg and 60 mg
HAYWARD, Calif., Apr 04, 2011 (BUSINESS WIRE) --
Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of patents listed by Takeda Pharmaceutical Company, Ltd. in connection with DEXILANT(R) (dexlansoprazole) delayed-release capsules, 30 mg and 60 mg.
Impax filed its Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic version of DEXILANT(R) with the U.S. Food & Drug Administration (FDA). Following receipt of the notice from the FDA that Impax's ANDA had been accepted for filing, Impax notified the New Drug Application holder and patent owner of its paragraph IV certification.
On April 1, Takeda Pharmaceuticals Co. LTD, Takeda Pharmaceuticals North America Inc., Takeda Pharmaceuticals LLC and Takeda Pharmaceuticals America Inc. filed suit for patent infringement against Impax in Northern District of California. This action formally initiates the patent challenge process under the Hatch-Waxman Act. Based on the filing date of the ANDA, the Company believes that it is the first to file an ANDA with a paragraph IV certification on the 30 mg capsule, and expects to be entitled to 180 days of market exclusivity.
Once the ANDA is approved by FDA, Global Pharmaceuticals, Impax's generic division, will commercialize the products.
DEXILANT(R) is used to treat gastroesophageal reflux disease (GERD), a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus (the tube between the throat and stomach). It is used to treat the symptoms of GERD, allow the esophagus to heal, and prevent further damage to the esophagus. DEXILANT(R) is in a class of medications called proton pump inhibitors. It works by decreasing the amount of acid made in the stomach. According to Wolters Kluwer Health, U.S. sales of DEXILANT(R) delayed-release capsules, 30 mg and 60 mg were approximately $20 million and $261 million, respectively, for the current 12 months ending January 2011.
I agree
Ford shares lead S&P higher on upgrade
April 4, 2011, 10:09 a.m. EDT
MARKET PULSE
SAN FRANCISCO (MarketWatch) -- Ford Motor Co. (F 15.70, +0.54, +3.56%) shares rallied almost 3% to $15.58 to lead the S&P 500 (SPX 1,334, +1.28, +0.10%) higher early Monday after Credit Suisse upgraded the stock to neutral from underperform. "Following disappointing 4Q10 results, a healthy dose of skepticism has made its way into the stock," analyst Chris Ceraso said. "However, beneath that caution, we believe investors are ready and willing to re-embrace Ford." Last week, Ford posted a 19% rise in March U.S. sales, with a total of 212,777 to wrestle the long-held top spot away from General Motors Co. (GM 32.43, +0.02, +0.05%) .